TLDR:
– Sound Bioventures joins a £19M financing round for UK oncolytic virus company Theolytics
– The funding will help Theolytics advance their lead candidate, THEO-260, through clinical trials
Sound Bioventures, a venture capital fund, has announced a new investment in Theolytics, a UK biotechnology company specializing in oncolytic viral therapies. The funding round raised a total of £19M ($24.5M) and included participation from M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises, and the University of Oxford.
The new funding will allow Theolytics to advance their lead candidate, THEO-260, through to clinical proof of concept. Plans are in place for a Phase 1 clinical trial in ovarian cancer to begin later this year, with a focus on demonstrating safe and effective administration of the candidate. THEO-260 has shown potential in killing cancer cells and immunomodulation in ovarian cancer patients.
Thomas Tan from Sound Bioventures will also be joining Theolytics’ Board of Directors. Both parties express excitement about the potential impact of THEO-260 in treating ovarian cancer patients and look forward to working together to bring this therapy to those in need.
Charlotte Casebourne Stock, CEO of Theolytics, is optimistic about the future of oncolytic viral therapies and welcomes Sound Bioventures as a new investor. Theolytics aims to bring better outcomes for patients with ovarian cancer through their innovative approach to developing targeted therapies suitable for systemic delivery.
Overall, the collaboration between Sound Bioventures and Theolytics represents a significant step forward in the field of oncolytic viral therapies, offering hope for patients with limited treatment options.
